CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer ...
40 million people live with HIV globally, and that number continues to rise. While therapies exist to reduce the amount of HIV in a patient's body and, in turn, reduce HIV symptoms, there remains no ...
It's my pleasure to be moderating this chat with the CEO of Voyager Therapeutics, Al Sandrock, who sure many folks know well from his current role and famous roles as prior. Al, maybe we can get into ...
The basic components of a virus are genetic material and a protein shell, called a capsid, that surrounds and protects the fragile nucleic acids. During the life cycle of a virus, the genetic material ...
CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus ...
The formation of viral particles was thought to be a sequential and irreversible process in which the assembly of one component generates a new site or conformational state that allows for the ...
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...
Biogen and Capsigen have entered into a strategic research collaboration to engineer novel AAV capsids to deliver gene therapies that address the underlying genetic causes of various central nervous ...
The genetic material of viruses is shielded by a protective protein covering called a capsid. Researchers in Spain have uncovered the strict selection rules that define capsid structure in spherical ...
Gene therapy developers rely on engineered viruses to carry genetic cargo to cells. Adeno-associated virus, the viral vector that has been the backbone of this burgeoning field, shows a particular ...
Figure 2: Co-localization of HP68 with HIV-1 Gag in mammalian cells. Figure 5: Anti-HuHP68 co-immunoprecipitates HIV-1 Vif but not Nef or RNase L. For purification, 3 ml of wheatgerm extract ...
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results